Comprehensive medication guide to {drug} including estimated pricing, availability information, side effects, and how to find it in stock at your local pharmacy.
Blujepa (Gepotidacin) is a first-in-class triazaacenaphthylene antibiotic manufactured by GSK. It was approved by the FDA in March 2025 for treating uncomplicated urinary tract infections (uUTIs) in female patients aged 12 and older (weighing at least 40 kg). In December 2025, it also received approval for uncomplicated urogenital gonorrhea in patients with limited or no alternative treatment options. Blujepa represents an entirely new class of antibiotics, offering an important option for patients dealing with antibiotic-resistant infections.
Blujepa works by inhibiting bacterial DNA replication through a novel mechanism. It targets two essential bacterial enzymes — DNA gyrase (topoisomerase II) and topoisomerase IV — by binding to a unique site on these enzymes that is distinct from where fluoroquinolones bind. This means Blujepa can be effective even against bacteria that have developed resistance to fluoroquinolone antibiotics like Ciprofloxacin or Levofloxacin. By blocking these enzymes, Blujepa prevents bacteria from replicating their DNA, ultimately killing the infection.
For uncomplicated UTIs, the typical regimen is 1,500 mg (two 750 mg tablets) twice daily for 5 days. For uncomplicated gonorrhea, the dose is 3,000 mg (four tablets) followed by another 3,000 mg approximately 12 hours later.
Blujepa (Gepotidacin) is a first-in-class antibiotic approved in March 2025, making it relatively new to the market. Because it is brand-only and manufactured solely by GSK, many pharmacies do not routinely stock it. While there is no active FDA shortage, patients may need to call multiple pharmacies or request a special order. Specialty pharmacies and larger chain pharmacies in urban areas are more likely to have it on hand. Medfinder can help you locate pharmacies with Blujepa in stock near you.
Struggling to find {drug} in stock? We'll call the pharmacies, sit on hold, and find you one that can fill your prescription.
Blujepa can be prescribed by a wide range of healthcare providers, including:
Telehealth consultations can also result in a Blujepa prescription for eligible patients with straightforward UTI or gonorrhea cases.
No, Blujepa is not a controlled substance. It is a prescription-only (Rx) antibiotic with no DEA scheduling. You will need a valid prescription from a licensed healthcare provider, but there are no special controlled substance restrictions on refills or dispensing.
Taking Blujepa after a meal can help reduce gastrointestinal side effects. Serious but rare side effects include QTc prolongation (irregular heartbeat), Clostridioides difficile-associated diarrhea, severe allergic reactions, and seizures. Contact your doctor immediately if you experience chest palpitations, severe or persistent diarrhea, or signs of an allergic reaction.
Blujepa is typically reserved for cases where first-line antibiotics are not suitable due to resistance, allergies, or other factors. Talk to your doctor about which option is best for you.
Always inform your healthcare provider about all medications, supplements, and herbal products you are taking before starting Blujepa.
Blujepa is a groundbreaking first-in-class antibiotic that offers a new treatment pathway for uncomplicated UTIs and gonorrhea — especially important as antibiotic resistance continues to grow. As a brand-name only medication from GSK, it can be expensive without insurance and may not be stocked at every pharmacy. If your doctor has prescribed Blujepa, use Medfinder to quickly locate pharmacies near you that have it in stock. Check with GSK's copay savings programs or the GSK For You patient assistance program (gskforyou.com or 1-888-825-5249) if cost is a concern.
%2C%20Color%3DOriginal.png)
